Upfront Treatment of Pediatric High-Risk Neuroblastoma With Chemotherapy, Surgery, and Radiotherapy Combination: The CCCG-NB-2014 Protocol

被引:6
作者
Zhang, Dongdong [1 ,2 ]
Kaweme, Natasha Mupeta [3 ]
Duan, Peng [4 ]
Dong, Youhong [2 ]
Yuan, Xiaojun [1 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Pediat Hematol Oncol, Shanghai, Peoples R China
[2] Hubei Univ Med, Xiangyang Peoples Hosp 1, Dept Oncol, Xiangyang, Peoples R China
[3] Wuhan Univ, Zhongnan Hosp, Dept Hematol, Wuhan, Peoples R China
[4] Hubei Univ Med, Xiangyang Peoples Hosp 1, Dept Obstet & Gynaecol, Xiangyang, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
关键词
neuroblastoma; high risk; CCCG-NB-2014; overall survival; N-myc; INTENSIVE INDUCTION CHEMOTHERAPY; BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; EVENT-FREE SURVIVAL; REFRACTORY NEUROBLASTOMA; INTERNATIONAL CRITERIA; CHILDREN; THERAPY; AGE; PROGRESSION;
D O I
10.3389/fonc.2021.745794
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeThe Chinese Children's Cancer Group developed the CCCG-NB-2014 study to formulate optimal treatment strategies for high-risk (HR) neuroblastoma (NB). The safety and efficacy of this protocol were evaluated. MethodPatients with newly diagnosed neuroblastoma and defined as HR according to the Children's Oncology Group study were included. They were treated with a combination of chemotherapy, surgery, and radiotherapy. The treatment-related toxicities, response rate, 3-year progression-free survival (PFS), and overall survival (OS) were analyzed. ResultsOf 159 patients enrolled between 2014 and 2018, 80 were eligible, including 19 girls and 61 boys, with a median age of 3.9 years (range 0.9-11). After a median follow-up of 24 months (range 3-40), the median OS was 31.8 months, and 3-year OS was 83.8%. In multivariate analyses, the OS was affected by N-MYC amplification (hazard ratio 0.212, 95% confidence interval (CI) 0.049-0.910; p = 0.037) and giant tumor mass (hazard ratio 0.197, 95% CI 0.071-0.552; p = 0.002). The median 3-year PFS was 25.8 months, and 3-year PFS was 57.5%. The univariate analysis showed that only the giant tumor mass was associated with the outcome. Of the 13 deaths, 11 died from the rapid progression of the disease and two from treatment-related toxicities. The most common adverse reaction was chemotherapy-induced hematological toxicity. ConclusionThe PFS and OS reported in our study were similar to Western countries. The CCCG-NB-2014 protocol proved to be an efficient regimen with tolerable side-effect for the treatment of pediatric HR-NB.
引用
收藏
页数:9
相关论文
共 43 条
  • [21] Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group
    London, WB
    Castleberry, RP
    Matthay, KK
    Look, AT
    Seeger, RC
    Shimada, H
    Thorner, P
    Brodeur, G
    Maris, JM
    Reynolds, CP
    Cohn, SL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (27) : 6459 - 6465
  • [22] Phase II Randomized Comparison of Topotecan Plus Cyclophosphamide Versus Topotecan Alone in Children With Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Study
    London, Wendy B.
    Frantz, Christopher N.
    Campbell, Laura A.
    Seeger, Robert C.
    Brumback, Babette A.
    Cohn, Susan L.
    Matthay, Katherine K.
    Castleberry, Robert P.
    Diller, Lisa
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (24) : 3808 - 3815
  • [23] Medical Progress: Recent Advances in Neuroblastoma.
    Maris, John M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (23) : 2202 - 2211
  • [24] Neuroblastoma
    Matthay, Katherine K.
    Maris, John M.
    Schleiermacher, Gudrun
    Nakagawara, Akira
    Mackall, Crystal L.
    Diller, Lisa
    Weiss, William A.
    [J]. NATURE REVIEWS DISEASE PRIMERS, 2016, 2
  • [25] Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study
    Matthay, Katherine K.
    Reynolds, C. Patrick
    Seeger, Robert C.
    Shimada, Hiroyuki
    Adkins, E. Stanton
    Haas-Kogan, Daphne
    Gerbing, Robert B.
    London, Wendy B.
    Villablanca, Judith G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (07) : 1007 - 1013
  • [26] Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: A new approaches to neuroblastoma therapy consortium study
    Matthay, KK
    Tan, JC
    Villablanca, JG
    Yanik, GA
    Veatch, J
    Franc, B
    Twomey, E
    Horn, B
    Reynolds, CP
    Groshen, S
    Seeger, RC
    Maris, JM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (03) : 500 - 506
  • [27] Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid
    Matthay, KK
    Villablanca, JG
    Seeger, RC
    Stram, DO
    Harris, RE
    Ramsay, NK
    Swift, P
    Shimada, H
    Black, CT
    Brodeur, GM
    Gerbing, RB
    Reynolds, CP
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (16) : 1165 - 1173
  • [28] Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma
    Matthay, KK
    Edeline, V
    Lumbroso, J
    Tanguy, ML
    Asselain, B
    Zucker, JM
    Valteau-Couanet, D
    Hartmann, O
    Michon, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (13) : 2486 - 2491
  • [29] The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report
    Monclair, Tom
    Brodeur, Garrett M.
    Ambros, Peter F.
    Brisse, Herve J.
    Cecchetto, Giovanni
    Holmes, Keith
    Kaneko, Michio
    London, Wendy B.
    Matthay, Katherine K.
    Nuchtern, Jed G.
    von Schweinitz, Dietrich
    Simon, Thorsten
    Cohn, Susan L.
    Pearson, Andrew D. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (02) : 298 - 303
  • [30] Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting
    Park, Julie R.
    Bagatell, Rochelle
    Cohn, Susan L.
    Pearson, Andrew D.
    Villablanca, Judith G.
    Berthold, Frank
    Burchill, Susan
    Boubaker, Ariane
    McHugh, Kieran
    Nuchtern, Jed G.
    London, Wendy B.
    Seibel, Nita L.
    Lindwasser, O. Wolf
    Maris, John M.
    Brock, Penelope
    Schleiermacher, Gudrun
    Ladenstein, Ruth
    Matthay, Katherine K.
    Valteau-Couanet, Dominique
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (22) : 2580 - +